2024
Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses
Roque D, Siegel E, Buza N, Bellone S, Huang G, Altwerger G, Andikyan V, Clark M, Azodi M, Schwartz P, Rao G, Ratner E, Santin A. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer (NCT03093155): Updated survival and subgroup analyses. BJC Reports 2024, 2: 43. PMCID: PMC11523995, DOI: 10.1038/s44276-024-00067-5.Peer-Reviewed Original ResearchPre-treated ovarian cancerOverall survivalBev armsDose reductionOvarian cancerTaxane responseRandomized phase 2 trialRandomized phase II trialPaclitaxel-resistant diseaseResultsThirty-seven patientsTreated with paclitaxelPhase 2 trialBiweekly bevacizumabDays 1,8,15Taxane-sensitiveUpdate survivalProgression-freePeritoneal cancerDose modificationTaxane sensitivityPlatinum resistanceSubset analysisSubgroup analysisResponse ratePatients
2023
Black-White differences in uterine cancer symptomatology and stage at diagnosis
Xu X, Chen L, Nunez-Smith M, Clark M, Ferris J, Hershman D, Wright J. Black-White differences in uterine cancer symptomatology and stage at diagnosis. Gynecologic Oncology 2023, 180: 118-125. PMID: 38091770, PMCID: PMC10922746, DOI: 10.1016/j.ygyno.2023.11.029.Peer-Reviewed Original ResearchAdvanced stage diagnosisWhite patientsPostmenopausal bleedingPatient characteristicsEnd Results-Medicare databaseBlack-white differencesBlack-White disparitiesBlack patientsUterine cancerCancer symptomsHigh riskPatientsAdvanced stageSymptomsDiagnosisCancer symptomatologyRegression modelsRiskLarge proportionBleedingHistologyCancerEpidemiologySymptomatologyMonthsICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging
AlAshqar A, Mutlu L, McNamara B, Harold J, Clark M, Huang G, Azodi M, Schwartz P, Santin A, Ratner E, Altwerger G, Andikyan V. ICG Fluorescence Technique for Detection of Sentinel Lymph Nodes in Laparoscopic Endometrial Cancer Staging. Journal Of Minimally Invasive Gynecology 2023, 30: s36. DOI: 10.1016/j.jmig.2023.08.110.Peer-Reviewed Original ResearchEndometrial cancer stagingSentinel lymph nodesLymph nodesCancer stagingSentinel lymph node identificationICG fluorescence techniqueTertiary care hospitalLymph node identificationICG techniqueSentinel lymphCare hospitalIntervention useStagingDye techniqueNode identificationLymphPatientsMalignancyHospitalDelayed presentation of placenta accreta following a first‐trimester medical abortion
Maurer J, Ramani S, Xu B, Gallousis S, Clark M, Andikyan V. Delayed presentation of placenta accreta following a first‐trimester medical abortion. Clinical Case Reports 2023, 11: e7849. PMID: 37636882, PMCID: PMC10457480, DOI: 10.1002/ccr3.7849.Peer-Reviewed Original ResearchChanges to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic
Sullivan M, Michel L, Wasser T, Clark M, Chudnoff S, Andikyan V. Changes to same day discharge after minimally invasive hysterectomy throughout COVID‐19 pandemic. Journal Of Obstetrics And Gynaecology Research 2023, 49: 1418-1423. PMID: 36808793, DOI: 10.1111/jog.15617.Peer-Reviewed Original ResearchConceptsRate of SDDSame-day dischargeInvasive hysterectomyDay dischargeCOVID-19 pandemicRetrospective chart reviewEmergency department visitsNumber of readmissionsMultivariable logistic regressionSame dayCommon gynecologic proceduresChi-square testChart reviewED visitsDepartment visitsHospital admissionElective surgerySurgical complexityGynecologic proceduresInclusion criteriaNosocomial infectionsHysterectomyPatientsLogistic regressionHealthcare systemRacial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries
Xu X, Chen L, Nunez-Smith M, Clark M, Wright J. Racial disparities in diagnostic evaluation of uterine cancer among Medicaid beneficiaries. Journal Of The National Cancer Institute 2023, 115: 636-643. PMID: 36788453, PMCID: PMC10248843, DOI: 10.1093/jnci/djad027.Peer-Reviewed Original ResearchConceptsAbnormal uterine bleedingWhite patientsUterine cancerFirst diagnostic procedureDiagnostic evaluationBlack patientsDiagnostic proceduresBlack-White disparitiesManagement visitsMarketScan Multi-State Medicaid DatabaseMulti-State Medicaid DatabaseUterine bleedingPatient characteristicsMedicaid databaseEarly diagnosisMedicaid beneficiariesMultivariable regressionPatientsCancerRacial disparitiesDiagnosisVisitsMore evaluationDisparitiesBleeding
2022
Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer
Piedimonte S, Kim R, Bernardini M, Atenafu E, Clark M, Lheureux S, May T. Validation of the KELIM score as a predictor of response to neoadjuvant treatment in patients with advanced high grade serous ovarian cancer. Gynecologic Oncology 2022, 167: 417-422. PMID: 37191644, DOI: 10.1016/j.ygyno.2022.10.014.Peer-Reviewed Original ResearchConceptsKaplan-Meier survival analysisOutcomes of cytoreductionRetrospective cohort studyDays of chemotherapyCA 125 valuesMeier survival analysisLocal ethics boardCytoreductive outcomeMedian pfsCohort studyInhibitor useTreatment delayFunctional statusBRCA statusInclusion criteriaHigh riskPlatinum sensitivityStage IIIPatientsSurvival analysisEthics BoardHigh gradeSignificant differencesNACTPoly adenosine
2018
Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection
Lee Y, Lee J, Paik E, Clark M, Kim R, Brown T, May T. Investigating the time intervals between primary cytoreductive surgery and initiation of adjuvant chemotherapy in patients with advanced epithelial ovarian cancer who had optimal cytoreduction surgery with bowel resection. Gynecologic Oncology 2018, 149: 98. DOI: 10.1016/j.ygyno.2018.04.226.Peer-Reviewed Original Research
2016
Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome
Clark M, Menderes G, Azodi M, Finberg K, Canosa S, Parkash V. Endometrial carcinoma as the presenting malignancy in an 18-year-old patient with Li-Fraumeni syndrome. Gynecologic Oncology 2016, 141: 183-184. DOI: 10.1016/j.ygyno.2016.04.473.Peer-Reviewed Original Research